Company Profile: Zoetis Inc. (ZTS)

ZTS insider trades (13 months) →

$82.99 −0.23% vs. previous close · Market cap $34.29B

Today's multi-factor rank: 436 of 461 · see the ranking

Quant500 Scores

Momentum

2.2/10

Value

4.7/10

Growth

4.2/10

Quality

5.6/10

Multifactor

4.2/10

Market and Valuation

Price & Market

Prev Close Price:$83.18

Open:$82.29

Day's Low:$81.53

Day's High:$83.73

Bid / Ask:-

Market Cap:34.29B

Enterprise Value:41.95B

52-Week Range

52-Week Low:$68.77

52-Week High:$132.49

Current position in 52-week range

52w Low-52w High

50-Day Avg:$75.16

200-Day Avg:$93.32

Volume

Volume Today:3,700,737

Avg Volume (3m):4,987,785

Avg Volume (10d):3,528,920

52-Week Change:-33.17%

vs S&P 500, 52 weeks:-

Beta:0.68

Valuation Multiples

P/E (trailing):13.67

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 6, 2026. The P/E is the price divided by that EPS.

P/E (forward):12.95

PEG Ratio:15.48

Price / Book:10.92

Price / Sales (TTM):3.60

EV / Revenue:4.40

EV / EBITDA:10.32

Dividends

Current yield:2.55%

Annual Dividend Rate:$2.12

Dividend Trailing:$2.06

Yield Trailing:2.48%

5-Year Avg Yield:0.93%

Payout Ratio:33.88%

Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-

Fiscal Year (Next):-

Date Filter (Month):

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):9.53B

Gross Profit:6.83B

EBITDA:4.07B

Net Income (TTM):2.64B

Rev Growth (YoY):-0.20%

Earnings Growth (YoY):+1.20%

Quarterly earnings growth (YoY):-4.80%

Margins

Gross Margin:-

EBITDA Margin:-

Operating Margin:-

Net Margin:-

Per Share

EPS Trailing (TTM):$6.07

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 6, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$6.41

Revenue Per Share:$22.14

Cash Per Share:-

Book Value:$7.60

Last Dividend:-

Ex-Dividend Date:-

Last Split:-

Balance Sheet & Liquidity

Total cash:1.68B

Total Debt:9.26B

Net Debt (Debt - Cash):7.58B

Debt / Equity:294.00%

Current Ratio:3.08

Quick Ratio:1.58

Cash Flows

Operating Cash Flow:2.84B

Free Cash Flow (FCF):2.02B

FCF Yield (FCF / Market Cap):-

Enterprise Value:41.95B

EV / Revenue:4.40

EV / EBITDA:10.32

Profitability

ROE (Return on Equity):64.91%

ROA (Return on Assets):15.35%

P/E (trailing):13.67

P/E (forward):12.95

Price / Book:10.92

PEG Ratio:15.48

52-Week Change:-33.17%

S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$6.07

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 6, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$6.41

P/E (forward):12.95

PEG Ratio:15.48

Growth and Margins

Earnings Growth YoY:-

Quarterly Earnings Growth YoY:-

Rev Growth YoY:-

Net Margin:-

Gross Margin:-

EBITDA Margin:-

Per Share

Revenue Per Share:$22.14

Cash Per Share:-

Book Value:$7.60

Cash Flows (TTM)

Free Cash Flow:2.02B

Operating Cash Flow:2.84B

EBITDA:4.07B

Total Revenue (TTM):9.53B

Net Income (TTM):2.64B

Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter	Period	Actual EPS	Estimated EPS	Difference	Surprise %	Currency

Ownership Structure

Ownership Distribution

% Insiders:-

% Institutional:-

% Inst. (of Float):-

No. of Institutions:-

Visual distribution

InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:413,223,602

Float (free shares):412,372,361

Short interest (shares):17,520,176

Short % of float:-

Short Ratio (days to cover):3.99

Short interest, prior month:-

Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-

Audit Risk:-

Board risk:-

Compensation Risk:-

Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization	Report Date	% Shares	No. Shares	Value (USD)	Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund	Report Date	% Shares	No. Shares	Value (USD)	Change %

Recent Insider Trades

Executive / Insider	Title	Date	Action	Shares

Options Chain

Expiration Date:

CALLS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

PUTS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

Zoetis Inc. (ZTS) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type	Date	Official link
8-K	2026-10-13	View filing ↗
8-K	2026-10-08	View filing ↗
8-K	2026-08-06	View filing ↗
11-K	2026-06-22	View filing ↗
SD	2026-05-28	View filing ↗
8-K	2026-05-22	View filing ↗
8-K	2026-05-20	View filing ↗
8-K	2026-05-07	View filing ↗
ARS	2026-04-08	View filing ↗
8-K	2026-02-12	View filing ↗

Company and Executive Profile

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

General Information

Headquarters:United States

City:Parsippany

Employees:14,500

Sector:Healthcare

Industry:Drug Manufacturers - Specialty & Generic

Website:-

Key Executives

Name	Title	Age	Total pay
Ms. Kristin C. Peck	CEO & Director	54	5.42M
Ms. Roxanne Lagano	Executive VP, General Counsel & Corporate Secretary	60	1.44M
Mr. Wetteny N. Joseph CPA	Special Advisor to the CEO	53	1.80M
Dr. Robert J. Polzer Ph.D.	Scientific Advisor	56	1.45M
Mr. Jamie Brannan	Executive VP & Chief Commercial Officer	52	1.74M
Mr. James K. Saccaro	Executive VP, CFO & COO	52	-
Mr. Keith Sarbaugh	Executive VP & Chief Digital and Technology Officer	46	-
Mr. Steven Frank	Vice President of Investor Relations	-	-

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Zoetis Inc. (ZTS): Quantitative Analysis

Name: Factor scores for Zoetis Inc. (ZTS)
Creator: Quant500
License: https://quant500.com/legal

Zoetis Inc. (ZTS) — Healthcare — Drug Manufacturers - Specialty & Generic. ZTS is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, ZTS has returned −32.4% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

ZTS ranks 436 of 461 on today's multifactor score, and 53 of the 55 Healthcare companies that score. Its strongest factor is quality (Z 0.37, ranked 100 of 468); its weakest is momentum (Z -1.67, ranked 488 of 494). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

Factor	Z-Score	Rank
Multifactor	-0.495	436 of 461
Momentum	-1.665	488 of 494 ↑1
Value	-0.208	266 of 489
Quality	0.367	100 of 468
Growth	-0.472	411 of 489

Market data

Metric	Value
Price	$82.99
Market Cap	34.29B
P/E	13.67
Revenue (last 12 months)	9.53B
Price / book	10.92
Book value per share	$7.60
52-week range	$68.77 – $132.49
Dividend yield	2.55%
Beta	0.68
Average volume	4,987,785
Shares outstanding	413.22M
Short interest (% of float)	4.80% (as of Oct 15, 2026)

When does ZTS report earnings? 12 of its last 12, before the open →

What are ZTS insiders doing? 87 transactions filed with the SEC, of them 3 buys and 1 sell, the last one on Sep 30, 2026 →

ZTS latest SEC filings

Annual report (10-K): filed Feb 12, 2026, fiscal year ended Dec 31, 2025 · see its 10-K filings on sec.gov
Quarterly report (10-Q): filed Aug 6, 2026, quarter ended Jun 30, 2026 · see its 10-Q filings on sec.gov
Earnings release (8-K): Aug 6, 2026, before the open · view the 8-K on sec.gov

Filing dates on EDGAR, the SEC's public registry. All ZTS filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Zoetis (ZTS)

When does Zoetis report earnings?

According to Nasdaq's public calendar (checked on Nov 4, 2026), Zoetis will report its next earnings on Nov 5, 2026, before the US market opens. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 12 before the open (SEC filings through Aug 6, 2026). ZTS earnings dates and times, quarter by quarter →

What is Zoetis's P/E ratio?

Zoetis's P/E (price over earnings per share for the last twelve months) is 13.7 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jun 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Zoetis is below its sector median. Healthcare stocks, company by company →

Where does Zoetis rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Zoetis ranks 436 of 461, and 53 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Zoetis insiders bought or sold shares?

The latest open-market purchase of Zoetis shares filed with the SEC (Form 4) was on May 13, 2026, by a director, for $501k. The latest sale was on Feb 17, 2026, by a director who is also an officer, for $2.5M. In total, from August 2025 through Nov 3, 2026: 3 purchases and 1 sale by directors, officers and large shareholders. All ZTS insider trades →

Does Zoetis pay a dividend?

Yes. Its dividend yield is 2.55% at the Nov 3, 2026 close (annual dividend of $2.12 per share). The latest recorded ex-dividend date is Oct 30, 2026.

What sector is Zoetis in, and which index?

Zoetis is classified in the Healthcare sector (industry: Drug Manufacturers - Specialty & Generic), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

Valuation multiples: P/E, P/B, EV/EBITDA and their trapsWhy the P/E and the price-to-book in the table above cannot be compared across sectors, and what a low P/E can hide.
Value and momentum: the two that have survived bestWhat the value and momentum scores on this page actually measure, and why they are the two factors that have best survived scrutiny.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
Sales growth: the driver that gets overestimated mostWhat sits behind the growth score and the twelve-month revenue, and why it is the number people extrapolate too far most often.
Dividends and payout: high is not always goodThis company pays a dividend and its yield is in the table above: when a high figure is good news and when it is a warning.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

Company Profile: Zoetis Inc. (ZTS)

Market and Valuation

Price & Market

52-Week Range

Volume

Valuation Multiples

Dividends

Valuation Context

Financial Statements TTM (Trailing 12 Months)

Income Statement

Margins

Per Share

Balance Sheet & Liquidity

Cash Flows

Profitability

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

Growth and Margins

Per Share

Cash Flows (TTM)

EPS Surprise History - Last 4 Quarters

Ownership Structure

Ownership Distribution

Shares & Short Interest

Governance Score (1=Best, 10=Worst)

Top Institutional Holders

Top Mutual Funds

Recent Insider Trades

Options Chain

CALLS

PUTS

Sentiment Metrics

Expected move

Zoetis Inc. (ZTS) SEC filings: 10-K, 10-Q and 8-K

Company and Executive Profile

General Information

Key Executives

You have seen the engine room

Zoetis Inc. (ZTS): Quantitative Analysis

Factor scores

Market data

ZTS latest SEC filings

Frequently asked questions about Zoetis (ZTS)

When does Zoetis report earnings?

What is Zoetis's P/E ratio?

Where does Zoetis rank on Quant500?

Have Zoetis insiders bought or sold shares?

Does Zoetis pay a dividend?

What sector is Zoetis in, and which index?

What is behind these numbers